Seminars in Hematology
Volume 44, Issue 2 , Pages 114-125 , April 2007

Quality Assurance Issues and Interpretation of Assays

  • Ian Mackie

      Affiliations

    • Haemostasis Research Unit, Haematology Department, University College London, London, UK.
    • Corresponding Author InformationAddress correspondence to Ian Mackie, PhD, Haemostasis Research Unit, UCL Haematology Department, First Floor, 51 Chenies Mews, London WC1E 6HX, UK.
    • ,
  • Peter Cooper

      Affiliations

    • Department of Coagulation, Royal Hallamshire Hospital, Sheffield, UK.
    • ,
  • Steve Kitchen

      Affiliations

    • Department of Coagulation, Royal Hallamshire Hospital, Sheffield, UK.

References 

  1. BCSH (British Committee for Standards in Haematology) Haemostasis and Thrombosis Task Force. Guideline: Investigation and management of heritable thrombophilia. Br J Haematol. 2001;114:512–528
  2. BCSH (British Committee for Standards in Haematology) Haemostasis and Thrombosis Task Force. Guideline: The investigation and management of neonatal haemostasis and thrombosis. Br J Haematol. 2002;119:295–309
  3. Favaloro EJ, Bonnar R, Sioufi J, Wheeler M, Low J, Aboud M, et al. Multilaboratory testing of thrombophilia: Current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology. Semin Thromb Hemost. 2005;31:49–58
  4. Meijer P, Haverkate F, Kluft K. Performance goals for the laboratory testing of antithrombin, protein C and protein S. Thromb Haemost. 2006;96:584–589
  5. Jennings I, Kitchen S, Woods TAL, Preston FE. Multilaboratory testing in thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program. Semin Thromb Hemost. 2005;31:66–72
  6. Kauffmann RH, Veltkamp JJ, Van Tilberg NH, Van Es LA. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Am J Med. 1978;65:607–613
  7. White B, Berry D. Review—Acquired antithrombin deficiency in sepsis. Br J Haematol. 2001;112:26–31
  8. Ceriello A, Dello Russo P, Zuccotti C, Florio A, Nazzaro S, et al. Decreased antithrombin III activity in diabetes may be due to non-enzymatic glycosylation—A preliminary report. Thromb Haemost. 1983;50:633–634
  9. The Antithrombin Mutation Database. (http://www1.imperial.ac.uk/medicine/about/divisions/is/haemo/coag/antithrombin/)
  10. Tran Tri H, Duckert F. Influence of heparin cofactor II (HCII) on the determination of antithrombin III (AT). Thromb Res. 1985;40:571–576
  11. Demers C, Henderson P, Blajchman MA, Wells MJ, Mitchell L, Johnston M, et al. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition. Thromb Haemost. 1993;69:231–235
  12. Beauchamp NJ, Pike RN, Daly M, Butler M, Makris M, Dafforn TR, et al. Antithrombin Wibble and Wobble (T85M/K): Archetypal conformational diseases with in vivo latent-transition, thrombosis, and heparin activation. Blood. 1998;92:2696–2706
  13. Perry DJ, Daly ME, Tait RC, Walker ID, Brown K, Beauchamp NJ, et al. Antithrombin Cambridge II (Ala384Ser): Clinical, functional and haplotype analysis of 18 families. Thromb Haemost. 1998;79:249–253
  14. Ungerstedt JS, Schulman S, Egberg N, Antovic J, Blomback M. Discrepancy between antithrombin activity methods revealed in antithrombin Stockholm: Do factor Xa-based methods overestimate antithrombin activity in some patients?. Blood. 1992;99:2271–2272
  15. Harper PL, Luddington RJ, Daly M, Bruce D, Williamson D, Edgar PF, et al. The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease. Br J Haematol. 1991;77:360–364
  16. Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: Effect of age, sex and blood group. Br J Haematol. 1994;86:798–803
  17. Walker ID. Reference ranges in haemostasis. In:  Rowan RM,  van Assendelft OW,  Preston FE editor. Advanced Laboratory Methods in Haematology. London, UK: Arnold; 2002;p. 338–351
  18. Dahlback B, Carlsson M, Svenson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A. 1993;90:1004–1008
  19. Rosen S, Johansson K, Lindberg K, Dahlback B. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost. 1994;72:255–260
  20. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, De Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369:64–67
  21. Beauchamp NJ, Daly ME, Cooper PC, Preston FE, Peake IR. Rapid two-stage PCR for detecting factor V G1691A mutation. Lancet. 1994;334:694–695
  22. De Visser MCH, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood. 1999;93:1271–1276
  23. Tosetto A, Rodeghiero F. Diagnosis of APC resistance in patients on oral anticoagulant therapy. Thromb Haemost. 1995;73:732–733
  24. De Ronde H, Bertina RM. Careful selection of sample dilution and factor V deficient plasma makes the modified APC resistance test highly specific for the factor V Leiden mutation. Blood Coagul Fibrinolysis. 1999;10:7–17
  25. Gardiner C, Cooper PC, Makris M, Mackie IJ, Malia RG, Machin SJ. An evaluation of screening tests for defects in the protein C pathway: Commercial kits lack sensitivity and specificity. Blood Coagul Fibrinolysis. 2002;13:155–163
  26. Toulon P, Halbmeyer WM, Hafner G, Schmitt Y, Randgard B, Odpadlik M, et al. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay (Results of a European multicenter evaluation). Blood Coagul Fibrinolysis. 2000;11:447–454
  27. Quincampoix JC, Legarff M, Rittling C, Andiva S, Toulon P. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation. Blood Coagul Fibrinolysis. 2001;12:569–576
  28. Guasch JF, Lensen RPM, Beryina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is “pseudo homozygous” for activated protein C resistance. Thromb Haemost. 1997;77:252–257
  29. Dargaud Y, Trzeciak MC, Meunier S, Angei C, Pellechia D, Negrier C, et al. Two novel factor V null mutations associated with activated protein C resistance/genotype discrepancy. Br J Haematol. 2003;123:342–345
  30. Cooper PC, Cooper SM, Smith JM, Kitchen S, Makris M. Evaluation of the Roche LightCycler: a simple and rapid method for direct detection of factor V Leiden and prothrombin G2010A genotypes from blood samples without the need for DNA extraction. Blood Coagul Fibrinolysis. 2003;14:499–503
  31. Patnaik M, Dlott JS, Fontaine RN, Subbiah MT, Hessner MJ, Joyner KA, et al. Detection of genomic polymorphisms associated with venous thrombosis using the Invader biplex assay. J Mol Diagn. 2004;6:137–143
  32. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363–365
  33. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature. 1984;339:237–238
  34. Preston FE, Kitchen S, Jennings I, Woods TA. A UK National External Quality Assessment scheme (UK NEQAS) for molecular genetic testing for the diagnosis of familial thrombophilia. Thromb Haemost. 1999;82:1556–1557
  35. Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci PM. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations—A cause for concern. Thromb Haemost. 2002;88:690–691
  36. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698–3703
  37. Itakura H, Telen MJ, Hoppe CC, White DAE, Zehnder JL. Characterization of a novel prothrombin variant, prothrombin C20209T, as a modifier of thrombotic risk among African-Americans. Thromb Haemost. 2005;3:2357–2359
  38. Wylenzek M, Geison C, Stapenhorst L, Wielckens K, Klingler KR. A novel point mutation in the 3′ region of the prothrombin gene at position 20221 in a Lebanese/Syrian family. Thromb Haemost. 2001;85:943–944
  39. Miletich J, Sherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med. 1987;317:991–996
  40. Koeleman BP, Reitsma PH, Allaart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood. 1994;84:1031–1035
  41. Tait RC, Walker ID, Islam SIA, Mitchell R, Conkie JA, Macall F, et al. Age related changes in protein C activity in healthy adult males. Thromb Haemost. 1991;65:326–327
  42. Guglielmone HA, Vides MA. A novel functional assay of protein C in human plasma and its comparison with amidolytic and anticoagulant assays. Thromb Haemost. 1992;67:46–49
  43. Pabinger I, Allaart CF, Hermans J, Briet E, Bertina RM Protein C transmitter group. Hereditary protein C deficiency: Laboratory values in transmitters and guidelines for the diagnosis procedure (Report on a study of the SSC subcommittee on protein C and protein S). Thromb Haemost. 1992;68:470–474
  44. D’Angelo SV, Gilardoni F, D’Angelo A. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S. Thromb Haemost. 1989;62:861–867
  45. Jennings I, Kitchen S, Cooper PC, Rimmer JE, Woods TAL, Preston FE. Further evidence that activated protein C resistance affects protein C coagulant activity assays. Thromb Haemost. 2000;83:171–172
  46. Marlar RA, Adcock DM, Madden RM. Hereditary dysfunctional protein C molecules (type II): Assay characterization and proposed classification. Thromb Haemost. 1990;63:375–379
  47. Bovill EG, Tomczak JA, Grant B, Bhushan F, Pillemer E, Rainville IR, et al. Protein C Vermont: Symptomatic type II protein C deficiency associated with two GLA domain mutations. Blood. 1992;79:1456–1465
  48. Mackie IJ, Gallimore M, Machin SJ. Contact factor proteases and the complexes formed with alpha 2-macroglobulin can interfere in protein C assays by cleaving amidolytic substrates. Blood Coagul Fibrinolysis. 1992;3:589–595
  49. Mikami S, Tuddenham EGD. Studies on immunological assay of vitamin-K dependant factors II (Comparison of four immunoassay methods with functional activity of protein C in human plasma). Br J Haematol. 1986;62:183–193
  50. Faioni EM, Hermida J, Rovida E, Razzari C, Asti D, Zeinali S, et al. Type II protein C deficiency: Identification and molecular modelling of two natural mutants with low anticoagulant and normal amidolytic activity. Br J Haematol. 2000;108:265–271
  51. Koeleman BP, van Rumpt D, Hamulyak K, Reitsma PH, Bertina RM. Factor V Leiden: An additional risk factor for thrombosis in protein S deficient families. Thromb Haemost. 1995;74:580–583
  52. Dykes AC, Walker ID, McMahon AD, Islam SI, Tait RC. A study of protein S antigen levels in 3788 healthy volunteers: Influence of age, sex and hormone use, and estimate for prevalence of deficiency state. Br J Haematol. 2001;113:636–641
  53. Makris M, Leach M, Beauchamp NJ, Daly ME, Cooper PC, Hampton KK, et al. Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S. Blood. 2000;95:1935–1941
  54. Woodhams BJ. The simultaneous measurement of total and free protein S by ELISA. Thromb Res. 1988;50:213–220
  55. Faioni EM, Franchi F, Asti D, Sacchi E, Bernadi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay. Thromb Haemost. 1993;70:1067–1071
  56. Cooper PC, Hampton KK, Makris M, Abuzenadah A, Paul B, Preston FE. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency. Br J Haematol. 1994;88:201–203
  57. Jennings I, Kitchen S, Woods TAL, Preston FE. Diagnostic errors in thrombophilia screening: Evidence from the UK NEQAS. Thromb Haemost Suppl. 1999;276:(suppl 1, abstr 867)
  58. Makris M. Hyperhomocysteinaemia and thrombosis. Clin Lab Haem. 2000;22:133–143
  59. Mezzano D, Munoz X, Martinez C, Cuevas A, Panes O, Aranda E, et al. Vegetarians and cardiovascular risk factors: Hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost. 1999;81:913–917
  60. Palmer-Toy DE, Szczepiorkowski ZM, Shih V, van Cott EM. Comparability of the Abbott Imx homocysteine assay with citrate-anticoagulated plasma and stability of homocysteine in citrated whole blood. Clin Chem. 2001;47:1704–1707
  61. Leino A. Fully automated measurement of total homocysteine in plasma and serum on the Abbott Imx analyzer. Clin Chem. 1999;45:569–571
  62. Rasmussen K, Moller J, Lyngbak M. Within-person variation of plasma homocysteine and effects of posture and tourniquet application. Clin Chem. 1999;45:1850–1855
  63. Tripodi A, Chantarangkul V, Lombardi R, Lecchi A, Mannucci PM, Cattaneo M. Multicenter study of homocysteine measurement—Performance characteristics of different methods, influence of standards on interlaboratory agreement of results. Thromb Haemost. 2001;85:291–295
  64. Jennings I, Kitchen S, Smith J, Woods TAL, Preston FE. Between-centre agreement in homocysteine assays: Experience from the UK NEQAS proficiency testing scheme. Thromb Haemost. 2002;87:921–922
  65. Tripodi A, Mannucci PM. Markers of activated coagulation and their usefulness in the clinical laboratory. Clin Chem. 1996;42:664–669
  66. Tripodi A, Chantarangkul V, Bottasso B, Mannucci PM. Poor comparability of Prothrombin fragment 1+ 2 values measured by 2 different commercial ELISA methods: Influence of different anticoagulants and standards. Thromb Haemost. 1994;71:605–608
  67. Hursting MJ, Slaughter TF, Stead AG, Szewczyk KM, Witt DJ, Greenberg CS. Standardisation of prothrombin fragment 1.2 measurement: Effects of pre-analytical variables and calibrator selection. Arch Pathol Lab Med. 1998;122:31–36

PII: S0037-1963(07)00002-9

doi: 10.1053/j.seminhematol.2007.01.001

Seminars in Hematology
Volume 44, Issue 2 , Pages 114-125 , April 2007

Article Tools

* Image Usage & Resolution